Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (62)

IV-01Khaled Abduljalil

Prediction of Tolerance to Caffeine Pressor Effect during Pregnancy using Physiologically Based PK-PD Modelling

Thursday 14:55-16:20

IV-02Rick Admiraal

Exposure to the biological anti-thymocyte globulin (ATG) in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards individualized dosing to improve survival

Thursday 14:55-16:20

IV-03

Mathematical Modelling of the Spread of Hepatitis C among Drug Users, effects of heterogeneity.

Thursday 14:55-16:20

IV-04

Comparison of NONMEM and Pmetrics Analysis for Aminoglycosides in Adult Patients with Cystic Fibrosis

Thursday 14:55-16:20

IV-05Nidal Huniti

A Nonlinear Mixed Effect Model to Describe Placebo Response in Children and Adolescents with Major Depressive Disorder

Thursday 14:55-16:20

IV-06Hesham Al-Sallami

Evaluation of a Bayesian dose-individualisation method for enoxaparin

Thursday 14:55-16:20

IV-07Oskar Alskär

Modelling of glucose absorption

Thursday 14:55-16:20

IV-08Helena Edlund

Clinical relevance of albumin concentration in patients with Crohn’s disease treated with infliximab for recommendations on dosing regimen adjustments

Thursday 14:55-16:20

IV-09Franc Andreu Solduga

Development of a Bayesian Estimator for Tacrolimus in Kidney Transplant Patients: A Population Pharmacokinetic approach.

Thursday 14:55-16:20

IV-10Yasunori Aoki

PopED lite an easy to use experimental design software for preclinical studies

Thursday 14:55-16:20

IV-11Eduardo Asín-Prieto

Population Pharmacokinetics of Cefuroxime in patients Undergoing Colorectal Surgery

Thursday 14:55-16:20

IV-12Ioanna Athanasiadou

Simulation of the effect of hyperhydration on urine levels of recombinant human erythropoietin from a doping control point of view

Thursday 14:55-16:20

IV-13

Modeling Erlotinib and Gefitinib in Vitro Penetration through Multiple Layers of Epidermoid and Colorectal Human Carcinoma Cells

Thursday 14:55-16:20

IV-14Aliénor Bergès

Dose selection in Amyotrophic Lateral Sclerosis: PK/PD model using laser scanning cytometry data from muscle biopsies in a patient study

Thursday 14:55-16:20

IV-15Shanshan Bi

Population Pharmacokinetic/Pharmacodynamic Modeling of Two Novel Neutral Endopeptidase Inhibitors in Healthy Subjects

Thursday 14:55-16:20

IV-16Bruno Bieth

Population Pharmacokinetics of QVA149, the fixed dose combination of Indacaterol maleate and Glycopyrronium bromide in Chronic Obstructive Pulmonary Disease (COPD) patients

Thursday 14:55-16:20

IV-17Roberto Bizzotto

Characterization of binding between OSM and mAb in RA patient study: an extension to TMDD models

Thursday 14:55-16:20

IV-18Marcus Björnsson

Effect on bias in EC50 when using interval censoring or exact dropout times in the presence of informative dropout

Thursday 14:55-16:20

IV-19Karina Blei

Mechanism of Action of Jellyfish (Carukia barnesi) Envenomation and its Cardiovascular Effects Resulting in Irukandji Syndrome

Thursday 14:55-16:20

IV-20Michael Block

Predicting the antihypertensive effect of Candesartan-Nifedipine combinations based on public benchmarking data.

Thursday 14:55-16:20

IV-21Michael Block

Physiologically-based PK/PD modeling for a dynamic cardiovascular system: structure and applications

Thursday 14:55-16:20

IV-22Irina Bondareva

Population Modeling of the Time-dependent Carbamazepine (CBZ) Autoinduction Estimated from Repeated Therapeutic Drug Monitoring (TDM) Data of Drug-naïve Adult Epileptic Patients Begun on CBZ-monotherapy

Thursday 14:55-16:20

IV-23Jens Markus Borghardt

Characterisation of different absorption rate constants after inhalation of olodaterol

Thursday 14:55-16:20

IV-25Karl Brendel

How to deal properly with change-point model in NONMEM?

Thursday 14:55-16:20

IV-26

Predicting Torsades de Pointes risk from data generated via high-throughput screening

Thursday 14:55-16:20

IV-27Margreke Brill

Population pharmacokinetic model for protein binding and subcutaneous adipose tissue distribution of cefazolin in morbidly obese and non-obese patients

Thursday 14:55-16:20

IV-28Brigitte Brockhaus

Semi-mechanistic model-based drug development of EMD 525797 (DI17E6), a novel anti-αv integrin monoclonal antibody

Thursday 14:55-16:20

IV-30Vincent Buchheit

Data quality impacts on modeling results

Thursday 14:55-16:20

IV-31Núria Buil Bruna

Modelling LDH dynamics to assess clinical response as an alternative to tumour size in SCLC patients

Thursday 14:55-16:20

IV-33Theresa Cain

Prediction of Rosiglitazone compliance from last sampling information using Population based PBPK modelling and Bayes theorem: Comparison of prior distributions for compliance.

Thursday 14:55-16:20

IV-34Vicente G. Casabo

Modification Of Non Sink Equation For Calculation The Permeability In Cell Monolayers

Thursday 14:55-16:20

IV-35Anne Chain

Not-In-Trial Simulations: A tool for mitigating cardiovascular safety risks

Thursday 14:55-16:20

IV-36Kalayanee Chairat

A population pharmacokinetics and pharmacodynamics of oseltamivir and oseltamivir carboxylate in adults and children infected with influenza virus A(H1N1)pdm09

Thursday 14:55-16:20

IV-37Quentin Chalret du Rieu

Hematological toxicity modelling of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor, in patients suffering from solid tumors or lymphoma: influence of the disease-progression on the drug-induced thrombocytopenia.

Thursday 14:55-16:20

IV-38Phylinda Chan

Industry Experience in Establishing a Population Pharmacokinetic Analysis Guidance

Thursday 14:55-16:20

IV-39Pascal Chanu

Simulation study for a potential sildenafil survival trial in adults with pulmonary arterial hypertension (PAH) using a time-varying exposure-hazard model developed from data in children

Thursday 14:55-16:20

IV-40Christophe Chassagnole

Virtual Tumour Clinical: Literature example

Thursday 14:55-16:20

IV-41Chao Chen

A mechanistic model for the involvement of the neonatal Fc receptor in IgG disposition

Thursday 14:55-16:20

IV-42Chunli Chen

Design optimization for characterization of rifampicin pharmacokinetics in mouse

Thursday 14:55-16:20

IV-43Nianhang Chen

Comparison of Two Parallel Computing Methods (FPI versus MPI) in NONMEM 7.2 on complex popPK and popPK/PD Models

Thursday 14:55-16:20

IV-44Marylore Chenel

Population Pharmacokinetic Modelling to Detect Potential Drug Interaction Using Sparse Sampling Data

Thursday 14:55-16:20

IV-45Jason Chittenden

Practical Application of GPU Computing to Population PK

Thursday 14:55-16:20

IV-46Yu-Yuan Chiu

Exposure-Efficacy Response Model of Lurasidone in Patients with Bipolar Depression

Thursday 14:55-16:20

IV-47Steve Choy

Modelling the Effect of Very Low Calorie Diet on Weight and Fasting Plasma Glucose in Type 2 Diabetic Patients

Thursday 14:55-16:20

IV-48Oskar Clewe

A Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells

Thursday 14:55-16:20

IV-49Teresa Collins

Performance of Sequential methods under Pre-clinical Study Conditions

Thursday 14:55-16:20

IV-50Francois Combes

Influence of study design and associated shrinkage on power of the tests used for covariate detection in population pharmacokinetics

Thursday 14:55-16:20

IV-51Emmanuelle Comets

Additional features and graphs in the new npde library for R

Thursday 14:55-16:20

IV-52Camille Couffignal

Population pharmacokinetics of imipenem in intensive care unit patients with ventilated-associated pneumonia

Thursday 14:55-16:20

IV-53Damien Cronier

PK/PD relationship of the monoclonal anti-BAFF antibody tabalumab in combination with bortezomib in patients with previously treated multiple myeloma: comparison of serum M-protein and serum Free Light Chains as predictor of Progression Free Survival

Thursday 14:55-16:20

IV-54Zeinab Daher Abdi

Analysis of the relationship between Mycophenolic acid (MPA) exposure and anemia using three approaches: logistic regression based on Generalized Linear Mixed Models (GLMM) or on Generalized Estimating Equations (GEE) and Markov mixed-effects model.

Thursday 14:55-16:20

IV-55Elyes Dahmane

Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients

Thursday 14:55-16:20

IV-56

A physiologically based pharmacokinetic model of oral drug bioavailability immediately post bariatric surgery

Thursday 14:55-16:20

IV-57Camila De Almeida

Modelling Irinotecan PK, efficacy and toxicities pre-clinically

Thursday 14:55-16:20

IV-58Willem de Winter

Population PK/PD analysis linking the direct acute effects of canagliflozin on renal glucose reabsorption to the overall effects of canagliflozin on long-term glucose control using HbA1c as the response marker from clinical studies

Thursday 14:55-16:20

IV-59Joost DeJongh

A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes.

Thursday 14:55-16:20

IV-60Paolo Denti

A semi-physiological model for rifampicin and rifapentine CYP3A induction on midazolam pharmacokinetics.

Thursday 14:55-16:20

IV-61Cheikh Diack

An indirect response model with modulated input rate to characterize the dynamics of Aβ-40 in cerebrospinal fluid

Thursday 14:55-16:20

IV-62Laura Dickinson

Population Pharmacokinetics of Twice Daily Zidovudine (ZDV) in HIV-Infected Children and an Assessment of ZDV Exposure Following WHO Dosing Guidelines

Thursday 14:55-16:20

IV-63

Using Bayesian-PBPK Modeling for Assessment of Inter-Individual Variability and Subgroup Stratification

Thursday 14:55-16:20

IV-64Christian Diestelhorst

Population Pharmacokinetics of Intravenous Busulfan in Children: Revised Body Weight-Dependent NONMEM® Model to Optimize Dosing

Thursday 14:55-16:20

IV-65Aris Dokoumetzidis

Bayesian parameter scan for determining bias in parameter estimates

Thursday 14:55-16:20